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standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates
are variable and factors inﬂuencing eﬃcacy and tolerability still remain incompletely deﬁned. We aimed to focus on SVR
rates and to identify factors inﬂuencing them in this meta-analysis.
Methods:MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncon-
trolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated
IFN and ribavirin therapy. Fourteen trials were included in the meta-analysis. Data on study populations, interventions,
and outcomes were extracted from trials using a random-eﬀects model. Primary outcome was the SVR rate.
Results:The pooled estimate of SVR rate was 16.3% (95% Conﬁdence Interval – 95% CI, 8.3–29.6%). There was a
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patients with cirrhosis or overweight. By meta-regression, higher SVR rate was observed in trials with a lower prevalence
of subjects with genotype 1 infection and with fewer overweight patients. The use of a 24-week retreatment stopping rule
did not aﬀect SVR rate.
Conclusions:The overall modest eﬃcacy argues against an indiscriminate retreatment with PEG-IFN and ribavirin of
all non-responders. Restricting retreatment to non-overweight patients or to those with genotype 2 or 3 infection, using a
24-week retreatment stopping rule, would optimize the potential beneﬁt with a scarce likelihood of missing a curative
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Since the early 2000s, at least 50% of patients with
chronic hepatitis C treated with standard a interferon
(IFN) and ribavirin combination therapy have not
responded to therapy. A large cohort of non-responders
(that is, subjects with detectable hepatitis C virus RNA
[HCV-RNA] 3 or 6 months after initiation of therapy)
thus exists within the pool of subjects with chronic hep-
atitis C. The clinical course of the disease can be more
severe in these patients, with an accelerated progression
towards end-stage liver disease [1] and development of
hepatocellular carcinoma [2]. Therefore, an eﬀective reg-
imen of retreatment is a major goal in the long-term
management of these patients.
Several studies of retreatment with pegylated IFN
(PEG-IFN) plus ribavirin in patients who failed to respond
to the combination of pegylated and non-pegylated IFN
plus ribavirin have been published [3–22]. The results of
these studies are inconclusive or conﬂicting because of the
relatively small samples and the diﬀerences in patient char-
acteristics, study design combining relapsers and non-
responders, doses of IFN and ribavirin administered in
the ﬁrst course, and retreatment regimens.
Although the American Association for the Study for
Liver Disease (AASLD) Practice Guidelines recommend
that retreatment with PEG-IFN plus ribavirin be con-
sidered for non-responders who have undergone previ-
ous regimens of combination treatment using non-
pegylated interferon [23], important questions still
remain unanswered. Is retreatment with PEG-IFN plus
ribavirin useful in all non-responders to the combina-
tion? Are there any diﬀerences in the eﬀectiveness of
retreatment between diﬀerent HCV genotypes, between
cirrhotic and non-cirrhotic patients and between diﬀer-
ent retreatment regimens? How useful might it be to
prolong retreatment up to 48 weeks also in patients
who have failed to clear HCV RNA by week 24?
To increase statistical power and to resolve uncer-
tainty we propose a meta-analysis of the available stud-
ies. The aims of this meta-analysis are: (1) to assess the
eﬃcacy and tolerability of retreatment in obtaining
SVR; (2) to analyze the variability in SVR rates by look-
ing at the heterogeneity among the studies as a means of
interpreting this variability; and ﬁnally, (3) to identify
possible predictors of SVR.2. Materials and methods
2.1. Selection of trials
This analysis was performed in accordance with the QUOROM
statement [24]. Retrieval of trials was based on the Cochrane Con-
trolled Trials Register, The Cochrane Library, MEDLINE and
EMBASE, using the following medical subject headings: chronic hepa-
titis C, non-responders, interferon and ribavirin, pegylated interferon,
retreatment, and clinical trial. The search was carried out in April2009 without a lower date limit on the search results. The computer
search was supplemented with manual searches for reference lists of
all retrieved review articles, primary studies and meeting abstracts in
order to identify other studies not found in the computer search.
Studies were included if they were randomized controlled trials or
prospective cohort studies, if they had been published or accepted for
publication as full-length papers, if they included patients with chronic
hepatitis C who were non-responders to standard or pegylated IFN
and ribavirin combination therapy who were retreated with pegylated
IFN plus ribavirin, and if non-response was deﬁned as detectable
serum HCV-RNA 3 or 6 months after initiation of therapy. In order
to assess publication bias we researched also for abstracts. Excluded
studies were identiﬁed with the reason for exclusion.
Of the 226 references identiﬁed through a MEDLINE search, 184
were excluded upon analysis of the abstract because they did not meet
inclusion criteria. Of the remaining 42 full-text articles, 30 were
excluded because they did not meet inclusion criteria, leaving 14 full-
length papers [3–16] meeting criteria for inclusion in the meta-analysis.
Finally, 6 abstracts identiﬁed by manual search [17–22], were also
included, only for the evaluation of the publication bias.
2.2. Review of the trials
The trials were ﬁrst reviewed using a list of predeﬁned, pertinent
questions that concerned the characteristics of patients, treatments,
outcomes and study validity. Each trial was evaluated and classiﬁed
by three independent investigators (F.B., A.L., G.C.). Discrepancies
among reviewers were infrequent (overall inter-observer variations
<10%), and were resolved by discussion. The methodological quality
of the studies was assessed by four principal criteria, as listed in Table
1 in Appendix. Each quality component was rated as yes or no. The
quality of trials was reported according to each separate component.
Since none of the trials met all quality criteria (see Table 1 in Appen-
dix), ‘‘good quality” studies were arbitrarily deﬁned as those that ful-
ﬁlled 2 of the 4 principal quality criteria.
2.3. Statistical analyses
Pooled estimates of SVR were calculated using random-eﬀects
logistic regression analysis after applying sample weights according
to the sample size, using SAS version 8.1 (SAS Institute, Cary, NC,
USA) software, PROC NLMIXED command. Heterogeneity among
studies was assessed with the Pearson v2-test. The assumption of heter-
ogeneity implied by the utilization of random-eﬀect models is justiﬁed
by the diﬀerences in patients’ features and study characteristics. A rec-
ommended approach to dealing with heterogeneity is sorting the heter-
ogeneous group of studies into subgroups according to a stratifying
variable suspected of having caused the inconsistency. Therefore, stra-
tum-speciﬁc rates of the SVR rates for diﬀerent patient-level and study-
level covariates were calculated. We used 11 stratifying variables: type
of publication, number of participating centers, study sample size,
mean age, percentage of males, mean BMI, percentage of genotype 1
infected subjects, percentage of cirrhotic patients, type of pegylated
interferon, dose of ribavirin, and study validity.
Only univariate logistic regression analyses were used to examine
the association between features of the study and the SVR rates. We
did not consider multivariate analysis because of the wide heterogene-
ity and lack of complete data for identiﬁcation of possible variables
that could explain heterogeneity.
Begg’s funnel plots were generated and Egger’s [25] regression
asymmetry test was used to examine potential publication bias related
to the SVR rate. For all analyses, a p of <0.05 was considered statisti-
cally signiﬁcant. All analyses were completed with SAS version 8.1
(SAS Institute, Cary, NC, USA) software.3. Results
3.1. Description of the studies
After review of the titles, 14 full papers fulﬁlled the
inclusion criteria and were selected for review. The main
Fig. 1. Forest plot of sustained virologic response rates in 14 full-length
papers.
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shown in Table 2 in Appendix. Fourteen, which
accounted for 3898 patients, were reported as full papers
[3–16]. Among the trials, three studies did not report the
number of participating centers, while all remaining
studies were multicenter trials, with the number of cen-
ters ranging from 2 to 133; among these studies 8
reported data on the prevalence of patients with cirrho-
sis (357/1282 = 27.8%). Regarding the design of the
study, 13 were prospective cohort studies while only 1
was RCT [16].
The percentage of males ranged from 60% to 84%.
The sample size of each study varied greatly, ranging
from 20 [14] to 1385 [15] patients. Mean patient age
was 47.8 years, ranging from 41.8 to 50.2. The propor-
tion of patients with cirrhosis ranged from 0% to 39%.
Data on the proportion of patients infected by genotype
1 were lacking in 4 trials and was high in all the studies
that reported this rate, ranging from 71% to 100%.
Among the full-length papers, four studies did not
report the body mass index (BMI). The average value
of BMI among the studies was 27.5 K/m2. The ﬁrst
treatment schedule was reported in ﬁve studies only
[6,8,10,11,15], showing a large variability in the doses
of standard IFN and ribavirin administered.
Among the 14 full-length papers, 7 studies deﬁned
non-response as detectable serum HCV-RNA 3 months
after initiation of therapy, 5 studies as detectable serum
HCV-RNA 6 months after initiation of therapy, while in
two studies the timing of HCV-RNA detection was not
reported.
With regard to the quality of the studies, the least
commonly fulﬁlled quality criteria were enrolment of
consecutive patients (10%), intention to treat analysis
(40%) and absence of case mix of non-responders to
IFN mono-therapy and to IFN plus ribavirin therapy
(40%) (Table 1 in Appendix). In 6 out of 14 studies
(43%), both non-responders and relapsers were
included. Eight studies [3,4,6–9,13,16] met our deﬁnition
for a ‘‘good quality study,” i.e. they fulﬁlled 2 or more of
the four principal pre-deﬁned quality criteria (Table 1 in
the Appendix).
3.2. Sustained virologic response rate
The therapeutic regimens of retreatment and the rate
of SVR of the studies are shown in Table 2 in Appendix.
A large variability of the retreatment regimens among
trials was found in the type of Peg-IFN (a-2a or a-2b);
the dose of Peg-IFN a-2b (ranging between 50 and
300 lg/week); and the dose of ribavirin (ranging
between 800 and 1400 mg/die). In all but one [16] of
the trials the length of retreatment was 48 weeks.
The SVR rate of the diﬀerent studies is shown in
Fig. 1. The 14 studies included 3898 patients. The
pooled estimate of the SVR rate was 16.3% (95% CI,8.3–29.6%). We found a remarkable heterogeneity in
the magnitude of the treatment eﬀect among the 14 stud-
ies (v2 for heterogeneity 159.5 with 19 DF; p < 0.0001).
The proportion of patients who achieved an SVR dif-
fered greatly among the studies, ranging from 7% [5]
to 30% [10]. A pooled analysis that excluded both these
outliers, reporting the highest [10] and lowest [5] beneﬁt
of retreatment, yielded similar results (SVR 15.4%, 95%
CI, 8–30%). The analysis of the remaining 13 studies,
after omission of the RCT that included non-responders
to a ﬁrst course of pegylated interferon plus ribavirin
[16], resulted in a similar eﬀect size (SVR 15.8%, 95%
CI, 6.2–33%).
Data on the SVR rate according to genotype infec-
tion (genotype 1 vs. genotype non-1) were reported in
7 trials only [6–9,11,12,15]. The pooled estimate of the
SVR rate in the subgroups of these 7 studies was
15.6% (95% CI, 12.4–19.4%) for genotype 1 and 33.9%
(95% CI, 25.8–43.1%) for patients infected by a geno-
type non-1 (p = 0.0001).
Since the 14 studies showed a marked heterogeneity,
stratiﬁed analyses were carried out in relation to type of
publication (full papers vs. abstracts), year of publica-
tion (2003–2005 vs. 2006–2009), sample size (6100 vs.
>100 patients), number of participating centers (613
vs. >13), mean age (649 vs. >49 years), percentage of
males (673% vs. >73%), mean BMI (628 vs. >28 Kg/
m2), percentage of genotype 1, (680% vs. >80%), per-
centage of cirrhosis (620% vs. >20%), type of Peg-
IFN, (a-2a or a-2b) ribavirin dose (6800 vs. >800 mg/
die), 24-week treatment-stopping rule (used vs. not
used), and study validity (high quality vs. low quality)
(Table 3 in Appendix).
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stratum of relevant study features, we next calculated
pooled estimates of the SVR rate within each stratum
and evaluated heterogeneity among strata. High (>20%)
SVR rates were observed when assessing data pooled
from studies including: (a) fewer than 100 patients; (b)
patients with a mean baseline BMI628 Kg/m2; (c) a per-
centage of genotype 1680%; (d) a percentage of patients
with cirrhosis of < 20%; and (e) patients retreated with
PEG-IFN a-2a (Table 3 in Appendix).
Similar SVR rates were observed when comparing
data pooled from studies that included patients who dis-
continued therapy at week 24 (SVR rate = 13.4%; 95%
CI, 5.0–30.9%) to studies that included patients who
completed 48 weeks of therapy (SVR rate = 16.7%;
95% CI, 7.2–34.1%). No diﬀerence in the magnitude of
the treatment eﬀect was observed between low quality
studies (SVR rate = 16.7%; 95%CI, 13–21.1%) and high
quality studies (SVR rate = 13.3%; 95%CI, 8.7–19.8%).
Heterogeneity was less evident in studies in which the
sample size was 6100, in which the number of partici-
pating centers was 613, in which the percentage of
patients with cirrhosis was <20%, and in which the mean
baseline BMI was 628 Kg/m2 (Table 3 in Appendix).
Heterogeneity persisted in all the remaining strata.
Logistic regression analysis was used to identify
potential sources of heterogeneity among the studies.
Using univariate meta-regression, among the 12 vari-
ables assessed, only three variables were signiﬁcantly
associated with an increased rate of SVR: low mean
baseline BMI (p = 0.0005), low percentage of patients
with genotype 1 infection (p = 0.005), and treatment
with Peg-IFN a-2a (p = 0.029).4. Safety
Retreatment with a course of 48 weeks of Peg-IFN
and ribavirin was not universally tolerated. Overall, side
eﬀects leading to withdrawal from both Peg-IFN andFig. 2. Box plot for patients who: (A) required dose reduction, (B) withdraw
percentage. The middle horizontal line in each box is the median, the upper a
indicates 90 percentile ranges.ribavirin retreatment occurred in 450 out of 3898
patients (11.6%; 95% CI, 10.5–12.6%) while 686 patients
(17.6%; 95% CI 16.4–18.9%) required dose reduction of
one or both drugs. Serious or life threatening (grade 3 or
4) adverse events were observed during treatment in 278
out of 3385 patients (7.1%; 95% CI, 6.3–8.0%). The dis-
tribution of the rate of adverse eﬀects leading to with-
drawal from therapy of patients who required dose
reduction and of those who complained of grade 3 or
4 adverse events is shown in Fig. 2.5. Publication bias
The plots and the Egger test for publication bias for
full papers and abstracts showed that the risk of having
missed or overlooked trials was not signiﬁcant: the p
value was 0.52 with the Egger test. This implies that
small studies with low SVR rates were as likely to be
published as large studies with high SVR rates. Similar
results were obtained when abstracts were excluded
from the analysis (p = 0.74).6. Discussion
This meta-analysis of data from 14 studies, compris-
ing nearly 4000 non-responders to combination therapy,
showed that retreatment with a course of 48 weeks of
PEG-IFN plus ribavirin achieves an SVR in 16% of
patients with a 12% withdrawal rate due to adverse reac-
tions or intolerance to drugs. Although the number of
retreated patients in the available studies was high, sug-
gesting that estimate of the cumulative SVR rate could
be robust, the conﬁdence intervals of the eﬀect were wide
(8.3–29.6%) due to the heterogeneity of the trials.
Our analysis demonstrates that heterogeneity of the
SVR rate after retreatment is a feature of these studies
and that it persists even in the stratum of high quality
studies, implying that the large variability of the clinicaln from therapy, (C) developed serious adverse events, expressed as a
nd lower line in each box indicate inter-quartile range, and the whisker
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tency in the SVR rate reported among trials is not sur-
prising if one considers diﬀerences in design and power
of the studies, potential biases in the selection of patients
with diﬀerent demographic, clinical and virologic char-
acteristics, the variability in the doses of standard IFN
and ribavirin, and the diﬀerent treatment stopping rule
of the ﬁrst course of therapy. Interestingly, heterogene-
ity disappeared in studies with a sample size 6100
patients, as well as in multicenter trials with few partic-
ipating centers, suggesting that complex therapies need
careful consideration before they can be routinely trans-
lated from large multinational trials into practice. A
large variability in the SVR rates was also observed in
studies that included more patients with cirrhosis or
overweight, indicating that a population with advanced
ﬁbrosis and/or metabolic abnormalities is more hetero-
geneous in terms of likelihood of achieving an SVR.
The low overall eﬃcacy and tolerability of retreat-
ment, even in the most responsive strata, as well as the
ensuing poor cost eﬀectiveness, do not lend support to
an indiscriminate retreatment of all non-responders to
combination therapy, as only a minority of non-
responders will eventually beneﬁt from retreatment with
pegylated interferon plus ribavirin.
In our analysis, the beneﬁt of retreatment on the SVR
rate was much more pronounced and statistically signif-
icant in patients with genotype non-1 infection, while we
failed to ﬁnd an improvement of the SVR rate in the
subgroup of patients with genotype 1 infection. Hence
the beneﬁts of retreatment may outweigh the risks for
patients with genotype 2 or 3 infection, whereas the risks
may outweigh the beneﬁts for patients with genotype 1
infection. However, data on the SVR rate according to
diﬀerent genotypes were lacking in several trials, and
caution must be exercised when interpreting results from
subgroup exploratory analyses.
Our analysis showed that studies that included
patients with normal baseline BMI, and low prevalence
of genotype 1 infection, and in which pegylated IFN a-
2a was administered, showed a higher SVR rate.
Although the mechanisms responsible for the eﬀect of
BMI on the SVR rate are unknown, a practical recom-
mendation to reduce body weight before starting retreat-
ment might achieve better SVR rates upon retreatment.
The slightly higher SVR rate observed when non-
responders were retreated with pegylated IFN a-2a
rather than pegylated IFN a-2b could be related to a
spurious association due to ecological bias. This meta-
analysis is not designed to ﬁnd an explanation to this
association, perhaps only a direct comparison, such as
the IDEAL study of treatment-naı¨ve patients [26], could
resolve this question.
We failed to ﬁnd a signiﬁcant diﬀerence in stratum-
speciﬁc SVR rates when comparing data pooled from
studies with high and low prevalence of cirrhoticpatients. However, our meta-analysis included a small
sample of patients with cirrhosis, hampering any ﬁrm
conclusion on the eﬀect of advanced ﬁbrosis on the like-
lihood of SVR.
Treatment discontinuation, treatment dose modiﬁca-
tion and serious adverse events occurred at extremely
variable rates in the trials included in the meta-analysis.
There was considerable variation in the dose of pegylat-
ed IFNs and ribavirin among the studies we evaluated,
suggesting that standardized regimens are needed to
obtain comparative data on eﬃcacy and safety, particu-
larly regarding the ribavirin dose. In our study, stratiﬁed
analysis by ribavirin dose failed to indicate a signiﬁcant
diﬀerence in the SVR rate between high and low dose of
ribavirin retreatment. Recently, a large multicenter RCT
[16] showed that retreatment with a regimen of pegylat-
ed a-2a 180 lg/week plus ribavirin 1000/1200 mg/die for
72 weeks produced a signiﬁcantly better SVR than high-
dose short duration therapy (360lg/week for 48 weeks),
at the cost, however, of signiﬁcantly more intolerance to
treatment. Since in all the studies included in this meta-
analysis a conventional course regimen of 48 weeks was
administered, we believe the available information is
inadequate to determine whether a longer course of
standard-dosage (180 lg/week for 72 weeks) could
achieve better results than a conventional course of stan-
dard-dose (180lg/week for 48 weeks). Further large-
scale multicenter RCTs will prove useful in substantiat-
ing the beneﬁt of retreatment of non-responders with a
prolonged course of therapy.
We found no conﬁrmation of Taliani and colleagues’
observation [6] that a prolongation of therapy beyond
24 weeks in HCV RNA-positive patients may further
increase the rate of SVR. Our meta-analysis provides
evidence that similar SVR rates were observed when
data pooled from studies discontinuing therapy at week
24 were compared to those continuing therapy to 48
weeks. So, in line with what has been observed in treat-
ment-naı¨ve patients treated with the same regimen, we
do not recommend prolonging to 48 weeks the retreat-
ment of patients who failed to achieve virologic response
by week 24. Moreover, based on the results of the trial
by Poynard et al. [15] and of the trial by Jensen et al.
[16] showing that patients with detectable HCV RNA
at week 12 were unlike to achieve SVR, the treatment
stopping role could be anticipated at week 12.
The results of this retrospective analysis are subject to
several limitations. Diﬀerences in the design, in the sam-
ple, in the baseline severity of illness in the population of
the studies, and in the re-treatment regimens may limit
the accuracy of this meta-analysis. We attempted to con-
trol for these diﬀerences by including covariates that
described the patients studied and the study design fea-
tures. Lack of data on other potential confounders, such
as the dose of standard IFN and ribavirin administered
during the initial course, could also aﬀect the accuracy
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summary data, and more detailed treatment compari-
sons could be made with a meta-analysis of individual
patient data (MIPD). However, it was documented the
increase in time and cost required by MIPD over
study-level analysis. In addition, it may not always be
possible to obtain IPD from all the studies, raising the
issue that the studies for which data are available may
represent a biased subset of the available studies.
As with all meta-analyses, this study also has the
potential limitation of the generalizability of results to
new populations and settings. Meta-analyses are likely
to have poor external validity when the included studies
all use the same limited patient population or are all
conducted in a single setting. As non-responders are a
heterogeneous population, we decided to include studies
with diﬀerent designs particularly nonrandomised trials
conducted in real clinical practice and those that
included non-responders to diﬀerent ﬁrst IFN courses
retreated with diﬀerent regimens. We believe that this
approach may have improved the generalizability of
our data to results observed in real clinical practice.
Finally, we are conﬁdent that publication bias was
not substantial and, therefore, unlikely to change the
direction of our pooled estimate of treatment eﬀect
and that the quality of individual trials seemed not to
bias the results of our meta-analysis.
What are the implications of this meta-analysis for
current practice? Concerning retreatment with a 48-
week course of pegylated IFN plus ribavirin of non-
responders to standard or pegylated IFN and ribavirin
combination therapy the available evidence is suﬃcient
to conclude that: 1) the modest overall eﬃcacy and tol-
erability, and the inconsistency in the reported SVR
rates amongst trials, argue against indiscriminate
retreatment for all non-responders; 2) restricting retreat-
ment to non-overweight patients or to those with geno-
type 2 or 3 infection optimizes the potential beneﬁt; 3)
due to its low probability of clinical beneﬁt the decision
to retreat subjects infected with HCV genotype 1 should
be assessed in the individual patient according to the
likelihood of disease progression and of adverse events;
and 4) stopping treatment in HCV RNA-positive
patients at 24 weeks is to be recommended.
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